Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-Bluebird Bio Temporarily Suspends Phase 1/2 And Phase 3 Studies Of LentiGlobin Gene Therapy For SCD

BY Reuters
— 7:09 AM ET 02/16/2021

Feb 16 (Reuters) - bluebird bio Inc:

* BLUEBIRD BIO ANNOUNCES TEMPORARY SUSPENSION ON PHASE 1/2 AND PHASE 3 STUDIES OF LENTIGLOBIN GENE THERAPY FOR SICKLE CELL DISEASE (BB1111) Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More BLUE News

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (BLUE)
GlobeNewswire - 4:05 PM ET 02/15/2021
Pomerantz Law Firm Announces the Filing of a Class Action against bluebird bio, Inc. and Certain Officers - BLUE
PR Newswire - 5:53 PM ET 02/12/2021
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
Business Wire - 6:59 AM ET 02/04/2021